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Case Presentation

A 61 year-old Caucasian female with a past medical history
significant for chronic lymphocytic leukemia (CLL) presented with
dark amber-colored urine, jaundice, and nausea for three days. She
reported increased fatigue and poor appetite but denied fever, chills,
shortness of breath, chest pain, vomiting, abdominal pain, diarrhea,
constipation, or bleeding. She denied any change in her medications
or recent travel history.
She was diagnosed with CLL two years ago and had undergone a
matched unrelated allogeneic stem cell transplant three months
ago. Her post transplant course was complicated by viremia with
cytomegalovirus (CMV) and Epstein-Barr virus (EBV), which were
successfully treated with foscarnet and rituximab, respectively.
Other past medical history included hypertension and basal cell
carcinoma of the face. Past surgeries included a cholecystectomy,
a hysterectomy, and bilateral knee replacements. She denied
alcohol use, smoking, or drug abuse. Medications on
admission included atenolol, a multivitamin, trimethoprim/
sulfamethaxazole, voriconazole, and valacyclovir. She was
allergic to codeine and lorazepam.
Vital signs on admission were stable. Physical exam was
significant for icteric sclera, jaundice, and mild abdominal
discomfort on palpation of the right upper quadrant. Admission
labs were notable for total bilirubin 14.9 mg/dL, direct bilirubin
7.2 mg/dL, alkaline phosphatase (AP) 421 IU/L, aspartate
transaminase (AST) 558 IU/L, and alanine amino transferase
(ALT) 738 IU/L. White blood cell count was 3 B/L with 75%
neutrophils, hemoglobin was 9.5 g/dL, and platelet count was
124 B/L. Her basic metabolic panel was within normal limits.
Her urinalysis was significant for 1+ bilirubin.
Jaundice and abnormal hepatic function tests in this patient with
the history of CLL and allogeneic stem cell transplant raised
concerns for active hepatitis, graft-versus-host disease (GVHD)
of the liver, drug toxicity, hepatic veno-occlusive disease, and
obstructive cholestasis.

Hospital Course

The patient underwent an abdominal ultrasonography with
dopplers that showed a normal liver status-post cholecystectomy
with no intrahepatic or extrahepatic ductal dilatation and
normal hepatic vasculature, ruling out obstructive cholestasis
and hepatic veno-occlusive disease. With her history of
CMV and EBV viremia, it was crucial to rule out residual or
recurrence of either infection. Her CMV viral load was less than
100 copies/ml (reference range <100 copies/ml), and EBV viral
load was less than 350 copies/ml (reference range <350 copies/
ml). Further laboratory studies for Hepatitis A, Hepatitis B,
and Hepatitis C were all negative. Adenovirus, which has been
increasingly known to cause disease in post transplant patients,1
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was also negative. A transjugular liver biopsy was done since
there was no obvious cause of elevated liver function tests
from the available laboratory studies. The liver biopsy revealed
mild portal inflammation and bile duct injury characteristic of
GVHD with moderate cholestasis.
With the diagnosis of GVHD of the liver, the patient was
immediately started on immunosuppressive therapy which
included high-dose methylprednisolone, tacrolimus, and
micophenolate mofetil. Although she continued to have
minimal clinical symptoms other than jaundice, she failed to
show significant improvement in her hepatic function tests.
By hospital day 15, the laboratory results were as follows: total
bilirubin 39.1 mg/dL, direct bilirubin 17.8 mg/dL, AP 557 IU/L,
AST 151 IU/L, and ALT 355 IU/L. While her transaminases were
trending down, total bilirubin, direct bilirubin, and AP were
worsening. Without much improvement with the conventional
immunosuppressive therapy, a monoclonal antibody called
muromonab or OKT3 was added. Muromonab, which is a
monoclonal antibody directed against the CD3 antigen closely
associated with the T-cell receptor, has been used as a second
line therapy in patients who did not respond to steroids for
GVHD.2 Even after the treatment with muromonab for 10 days,
her hepatic function tests did not improve significantly: total
bilirubin 30.3 mg/dL, direct bilirubin 12.7 mg/dL, AP 436 IU/
L, AST 78 IU/L, and ALT 104 IU/L. She was discharged with
oral corticosteroids for continued treatment of her GVHD of
the liver. At this time, it is difficult to predict whether she will
recover completely from the GVHD. Of note, the treatment of
her GVHD was complicated by a rise in her CMV viral load on
day 24 of her hospital stay to 375 copies/mL and clostridium
difficile enterocolitis.

Discussion

Hematopoetic stem-cell transplantation is an important and
common treatment in malignancies and multiple hematologic
disorders. In the early 1960s, allogeneic transplantation
became feasible after the identification and typing of HLA, the
major histocompatibility complex.3 In the 1970s, Thomas and
colleagues conducted successful allogeneic stem cell transplants
in end-stage leukemic patients and achieved first remissions
in more than half of their patients,3 thus laying a foundation
for use of this treatment in conjunction with conventional
chemotherapy and radiation.
When allogeneic stem cell transplantation takes place,
unsuppressed donor T-cells can recognize either major
histocompatibility or minor histocompatibility antigens of
a recipient, which leads to the activation of the donor T-cells
against the recipient’s organs. This phenomenon is also known
as graft-versus-host disease (GVHD).

Case Reports

GVHD that occurs within 100 days after transplantation is
considered acute GVHD, as was the case for this patient. GVHD
that occurs after 100 days is considered chronic. Both types of
GVHD occur more frequently with cases involving older patients,
unrelated donors, older donors, CMV-positive donors, female
donors, and donors with previous pregnancies or transfusion
sensitization.4 Clinically significant GVHD happens in 30% to
50 % of recipients of allogeneic hematopoietic transplants.4
The primary target organs in GVHD are the skin, liver,
gastrointestinal tract, and the hematopoietic system. The liver
is the second most commonly involved organ in acute GVHD,
and manifests with abnormal liver function tests.5 The earliest
and most common finding is the rise in direct bilirubin and
alkaline phosphatase, which is explained by the fact that GVHD
causes damage to bile canaliculi and results in cholestasis.
The rise in direct bilirubin and alkaline phosphatase is
nonspecific, however, so other causes of hepatic damage require
evaluation. Hepatic infections, primarily viral hepatitis, must be
ruled out since many of these patients are immunocompromised
and are at an increased risk of infection. Another important
diagnosis to consider is hepatic veno-occlusive disease, which is
characterized by obstruction in the hepatic circulation as result
of damaged sinusoidal endothelium.3 Total-body irradiation and
chemotherapy that are used as preparative agents for stem cell
transplant are the cause of this relatively common complication.
Patients with hepatic veno-occlusive disease present with painful
hepatomegaly, jaundice, and retain fluid.3 Another diagnosis
to consider is drug toxicity from chemotherapeutic drugs,
corticosteroids, antibiotics, antifungal agents, and anti-GVHD
drugs.1 Biopsy is the definitive method to diagnose GVHD of
the liver, and transjugular liver biopsy may be preferable over
percutaneous liver biopsy due to the high bleeding risk since
many of these patients are thrombocytopenic. Transjugular
biopsy may be also helpful in assessing the hepatic venous
pressure gradient to identify hepatic veno-occlusive disease.1
The first and most effective treatment of GVHD is the use of
glucocorticoids. Research suggests that starting with low dose
steroids (2mg/kg per day) is appropriate; randomized studies

showed no difference in mean response rates or actual survival
rates between different dosages of steroids. If glucocorticoids
are not successful, other immunosuppressive drugs such
as cyclosporine, tacrolimus, antithymocyte globulin, or
mycophenolate mofetil may be considered. If these treatment
strategies fail, then a more aggressive approach such as using
extracorporeal photophoresis and monoclonal antibodies
directed against CD 25, TNF-alpha, T-cell receptor, and IL-2
receptor may be considered.2
In summary, this is a case of a 61 year-old female with a history
of CLL status-post allogeneic stem cell transplant who presented
with jaundice and a rise in bilirubin and alkaline phosphatase on
laboratory testing, which raised concerns for possible GVHD of
the liver. However, it was very important to consider all other
disease possibilities. Especially in this case, a distinction between
an active infection versus graft-versus-host disease was crucial as
immunosuppressive therapy would have worsened the patient’s
condition if the cause had been an active infection. The patient
underwent a transjugular liver biopsy that was consistent with
the GVHD of the liver, and she has been on different regimens
of immunosuppressive drugs. The immunosuppressive therapy
for the GVHD led to the complications of elevation of the CMV
viral load and clostridium difficile infection, which highlights
the fact that sometimes medicines intended for treatment can in
effect cause harm. This reinforces the lesson to always weigh the
benefits against the risks when choosing to implement a therapy.
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